UV Partners, Inc.

UV Partners, Inc., operating as Pelion Venture Partners, is a venture capital firm founded in 1986 and headquartered in Salt Lake City, Utah, with an additional office in Manhattan Beach, California. The firm specializes in early-stage investments, focusing primarily on information technology and life sciences sectors. Within information technology, Pelion targets areas such as software, SaaS, cloud computing, financial technology, and cybersecurity, while its life sciences investments include biotechnology and medical devices. Pelion typically invests between $0.5 million and $10 million in individual companies, often acting as a lead investor and taking board seats in its portfolio. The firm favors companies based in the Western United States, particularly in regions like the Intermountain West and Southern California, and actively supports entrepreneurs in smaller markets such as Boise and Phoenix. With a team of seven investment professionals, Pelion adopts a hands-on approach, collaborating closely with its portfolio companies to help transform early-stage concepts into industry-leading enterprises.

Chris Cooper

General Partner

Susannah Duke

Principal

Steve Glover

Chief Financial Officer

Tyler Hogge

Venture Partner

Peter W. Johnson

MD

Jeff Kearl

General Partner

Benjamin Lambert

Principal

Ben Lambert

General Partner

Carl S. Ledbetter

Special Partner

Trevor Lund

Vice President of Finance

Jaquie McKay

Financial Advisor

Matt Mosman

General Partner

Kimberly (Kim) Mueller

Chief Finance Officer

Kristy Muir

Senior Associate

Robert D. Pavey

Member of Advisory Board

Holly Preslar

Senior Associate

Skyler Seymour

Senior Associate

Daylor Youngblood

Investment Associate

Past deals in Oregon

UpGuard

Series B in 2021
UpGuard's proprietary technology tests an organization's IT infrastructure both internally and externally and calculates the potential risk for future intrusions and outages. Upon evaluating the ongoing configuration state of every server and network device, companies are given an easy-to-understand score called CSTAR — a single number which indicates to IT staff as well as their executives their risk level for data breaches. An organization's CSTAR score can even be used by corporate insurers in creating a cybersecurity insurance policy. Thousands of companies, including ADP, E*TRADE, and Cisco Systems, use UpGuard to validate infrastructure, continuously detect risks, and procure cybersecurity insurance. UpGuard is headquartered in Mountain View, California with offices in Portland, Oregon.

UpGuard

Series B in 2016
UpGuard's proprietary technology tests an organization's IT infrastructure both internally and externally and calculates the potential risk for future intrusions and outages. Upon evaluating the ongoing configuration state of every server and network device, companies are given an easy-to-understand score called CSTAR — a single number which indicates to IT staff as well as their executives their risk level for data breaches. An organization's CSTAR score can even be used by corporate insurers in creating a cybersecurity insurance policy. Thousands of companies, including ADP, E*TRADE, and Cisco Systems, use UpGuard to validate infrastructure, continuously detect risks, and procure cybersecurity insurance. UpGuard is headquartered in Mountain View, California with offices in Portland, Oregon.
Artielle ImmunoTherapeutics, Inc. is a biopharmaceutical company based in Tigard, Oregon, that develops biologic drugs aimed at treating inflammatory and degenerative diseases. Founded in 2004, the company specializes in therapies for neuro-inflammatory conditions such as multiple sclerosis, optic neuritis, and stroke, as well as autoimmune diseases like rheumatoid arthritis, celiac disease, and type 1 diabetes. Artielle's primary focus includes the development of recombinant T-cell receptor ligands (RTLs), specifically RTL1000 for multiple sclerosis, which target the CD74 receptor on monocytes to inhibit the action of macrophage migration inhibitory factor. Through its innovative platform, Artielle aims to address significant unmet medical needs in the treatment of various debilitating conditions.